Email: info@apollotherapeutics.comTranslating innovative science into therapeutic potential

Apollo People

Dr Richard Butt

Apollo Therapeutics CEO

Dr Richard Butt

Richard has 20 years’ experience in pharmaceutical drug discovery and development from working on the earliest novel ideas to Ph3 programmes. Richard is a cell biologist with a degree in biochemistry from the University of York and PhD from University College London, from where he joined Pfizer in 1996. Richard developed his technical experience and leadership skills as a lead biologist across multiple therapy areas, within drug safety/safety pharmacology and for the last few years leading clinical translational strategy in the Pain and Neuroscience therapy area. Richard has lead 7 programmes to clinical candidate selection, developed IND/CTA-enabling and preclinical regulatory packages for many assets, and led >30 clinical studies spanning Ph0 to Ph2 designs, execution and delivery. Richard’s passion is in project and portfolio leadership in the pre-clinical and clinical translational space and this fits perfectly with the remit and mission of Apollo Therapeutics and as leader of the drug discovery team.